AtriCure, Inc. (NASDAQ:ATRC – Get Free Report) Director Karen Prange sold 3,564 shares of the company’s stock in a transaction dated Wednesday, August 5th. The stock was sold at an average price of $38.80, for a total transaction of $138,283.20. Following the transaction, the director owned 22,809 shares in the company, valued at $884,989.20. The trade was a 13.51% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
Karen Prange also recently made the following trade(s):
- On Wednesday, May 20th, Karen Prange sold 3,000 shares of AtriCure stock. The shares were sold at an average price of $28.65, for a total transaction of $85,950.00.
AtriCure Price Performance
Shares of NASDAQ:ATRC opened at $41.39 on Friday. The business’s 50 day simple moving average is $32.25 and its 200-day simple moving average is $31.38. The firm has a market capitalization of $2.11 billion, a price-to-earnings ratio of 197.10 and a beta of 1.20. The company has a debt-to-equity ratio of 0.14, a current ratio of 4.22 and a quick ratio of 3.19. AtriCure, Inc. has a 12 month low of $25.36 and a 12 month high of $43.18.
Analyst Ratings Changes
A number of research analysts have recently weighed in on the company. Canaccord Genuity Group raised their price target on AtriCure from $53.00 to $55.00 and gave the company a “buy” rating in a research report on Wednesday, May 6th. Zacks Research upgraded shares of AtriCure from a “hold” rating to a “strong-buy” rating in a research report on Friday, July 24th. UBS Group lowered their price objective on shares of AtriCure from $55.00 to $50.00 and set a “buy” rating on the stock in a research note on Tuesday, July 28th. Weiss Ratings upgraded shares of AtriCure from a “sell (e+)” rating to a “sell (d+)” rating in a report on Tuesday, July 28th. Finally, Citigroup restated a “market outperform” rating on shares of AtriCure in a research report on Tuesday, July 21st. Two equities research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $48.50.
View Our Latest Analysis on AtriCure
Hedge Funds Weigh In On AtriCure
Several hedge funds have recently bought and sold shares of ATRC. Oak Harvest Investment Services acquired a new position in shares of AtriCure in the fourth quarter worth $1,484,000. Massachusetts Financial Services Co. MA boosted its stake in shares of AtriCure by 20.4% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 511,213 shares of the medical device company’s stock valued at $20,224,000 after acquiring an additional 86,532 shares during the last quarter. F m Investments LLC purchased a new stake in AtriCure during the 4th quarter worth about $2,872,000. Vanguard Group Inc. increased its position in AtriCure by 1.3% during the 4th quarter. Vanguard Group Inc. now owns 4,903,755 shares of the medical device company’s stock worth $193,993,000 after purchasing an additional 62,861 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership acquired a new position in AtriCure in the 1st quarter valued at about $7,922,000. Hedge funds and other institutional investors own 99.11% of the company’s stock.
About AtriCure
AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.
The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.
Featured Articles
- Five stocks we like better than AtriCure
- Quantum Earnings Week: Winners and Losers Are Finally Emerging
- Axon’s Post-Earnings Pullback May Be More About Valuation Than Growth
- Uber Stock Lags in 2026, But Cash Flow and AV Bets Fuel Upside
- AppLovin Stock Hits 52-Week Low as Analysts Trim Targets, Stay Bullish
Receive News & Ratings for AtriCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure and related companies with MarketBeat.com's FREE daily email newsletter.
